In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Icecure Medical (ICCM – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $1.12.
Chen covers the Healthcare sector, focusing on stocks such as Oculis Holding, Anixa Biosciences, and Ocular Therapeutix. According to TipRanks, Chen has an average return of -31.7% and a 23.83% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Icecure Medical with a $3.67 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $4.73 and a one-year low of $0.75. Currently, Icecure Medical has an average volume of 148.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Icecure Medical Ltd is a Israel based firm which develops and markets minimally invasive cryoablation therapies for women’s health. The company provides a minimally invasive, in-office definitive treatment for symptomatic breast fibroadenoma.
Read More on ICCM:
- IceCure Medical management to meet with Oppenheimer
- IceCure Medical appoints Good as VP of Sales for North America
- IceCure Medical price target lowered to $4 from $4.25 at Alliance Global
- IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum
- IceCure Medical management to meet with Maxim
